These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20532476)

  • 1. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
    Home PD; Kahn SE; Jones NP; Noronha D; Beck-Nielsen H; Viberti G; ;
    Diabetologia; 2010 Sep; 53(9):1838-45. PubMed ID: 20532476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer and bone fractures in observational follow-up of the RECORD study.
    Jones NP; Curtis PS; Home PD
    Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Dargie H; Komajda M; Gubb J; Biswas N; Jones NP
    Diabetologia; 2005 Sep; 48(9):1726-35. PubMed ID: 16025252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
    Home PD; Pocock SJ; Beck-Nielsen H; Curtis PS; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    Lancet; 2009 Jun; 373(9681):2125-35. PubMed ID: 19501900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
    Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
    Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
    Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
    Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
    N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ
    Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
    Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
    PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Haffner SM; Viberti G; Herman WH; Lachin JM; Kravitz BG; Yu D; Paul G; Holman RR; Zinman B;
    Diabetes Care; 2010 Jan; 33(1):177-83. PubMed ID: 19808911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
    Setter SM; Iltz JL; Thams J; Campbell RK
    Clin Ther; 2003 Dec; 25(12):2991-3026. PubMed ID: 14749143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM; Henley WE; Weedon MN; Lonergan M; Rodgers LR; Jones AG; Hamilton WT; Sattar N; Janmohamed S; Holman RR; Pearson ER; Shields BM; Hattersley AT;
    Diabetes Care; 2018 Sep; 41(9):1844-1853. PubMed ID: 30072404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
    Vaughan EM; Rueda JJ; Samson SL; Hyman DJ
    Curr Diabetes Rev; 2020; 16(8):851-858. PubMed ID: 32026779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.